Post-earnings recap
Reported
Thu, Aug 13, 2026
EPS actual
$-1.05
EPS est.
$-0.97
EPS surprise
-8.25%
1-day move
-7.90%
Kodiak Sciences reported a larger-than-expected loss per share, which contributed to a significant drop in its stock price by 7.9%. The company did not provide revenue figures, and there was no guidance update. Investors may be concerned about the company's financial health given the EPS miss.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-1.05 | $-0.92 | -8.25% |
| Revenue | $0M | $0M | N/A |
No transcript is on record, and the analysis is based solely on numerical results.
Kodiak Sciences Inc. is a biotechnology company focused on developing innovative therapies for serious eye diseases. Operating in the health care sector, Kodiak's work is critical as it addresses significant unmet medical needs in vision care, which is increasingly important given the aging population.
Last quarter
In Q1-2026, Kodiak reported an EPS of $-0.94, slightly missing analyst expectations. The stock reacted negatively, dropping 4.82% the following day.
EPS beat streak
0Q
EPS beat rate
25%
Avg EPS surprise
-4.65%
Avg 1-day reaction
-1.16%
Analysts are anticipating a loss of $-0.92 per share, with no revenue expected. The market is closely watching for any signs of progress in product development.
Bull case
If Kodiak can beat EPS expectations and provide positive updates on its pipeline, it could signal strong future growth potential, leading to a stock price increase.
Bear case
Conversely, if Kodiak misses EPS estimates again without any revenue, it could raise concerns about the viability of its product pipeline and lead to further stock declines.
Key metrics to watch
EPS
$-0.92Earnings per share is a key indicator of the company's profitability and financial health.
Revenue
$0MWhile revenue is expected to be zero, any deviation could indicate progress in product development or market entry.
The print will turn on these.
Q1
Will Kodiak's EPS exceed the consensus estimate of $-0.92?
A better-than-expected EPS could indicate improved operational efficiency or progress in its drug development pipeline.
Q2
Is there any update on product development or potential revenue generation?
Any positive news regarding product advancements could significantly influence investor sentiment and stock performance.
—
Est. EPS
$0.20
Est. Rev
$1.1B
Impl. Move
±17.5%
Why consensus could be wrong
The consensus may underestimate the potential for Kodiak to surprise on EPS due to recent advancements in its pipeline that have not been fully recognized.
Supporting evidence
The options market is pricing a 39.1% move, indicating that traders expect significant volatility, which could imply a surprise.
Kodiak's historical performance shows that it has occasionally exceeded expectations despite a challenging environment.
Key risk
If Kodiak reports an EPS significantly better than $-0.92, it could shift market sentiment dramatically.
Pre-commit to what would confirm each case.
The market is debating Kodiak's ability to turn its pipeline into viable products, with earnings performance being a critical factor.
Bull confirmed if
A reported EPS better than $-0.92, alongside any positive news on product development, would support a bullish outlook.
Bear confirmed if
An EPS worse than $-1.04, with no updates on revenue generation, would confirm a bearish outlook.
What the market is pricing for the move.
Implied Move
±39.1%
Historical Avg
±5.2%
The options market is pricing in a significant potential move in either direction, indicating high uncertainty around the earnings report.
Options are pricing ±39.1% while KOD has averaged ±5.2% over the last 8 prints — setup is pricing rich.
ATM IV
0.9%
30d HV
60.4%
Cross-company pattern from 30 similar setups.
Prior-quarter miss + options pricing rich in Health Care
Fade rate: 14 of 29 (48%)
This setup has occurred 30 times across Health Care in the last 2 years. 14 of 29 faded and 15 held — no strong directional bias after the initial reaction. The average absolute 1-day move is 3.7%, with a raw directional average of -1.3% (modestly negative historical bias).
Likely market behavior by outcome. Not investment advice.
Beat & raise
If Kodiak beats expectations, history suggests the stock could see a positive reaction, potentially around a 1.5% increase.
In line / cautious
If results are in line with expectations, the stock may experience muted movement as investors await further guidance.
Miss
Should Kodiak miss expectations, history suggests a potential decline of around 0.1% based on past performance.
The lines on the call that would change the story.